Pacific Biosciences of California, Inc. (PACB) stock
PACBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
$1.83+0.01 (+0.55%)
Close on Nov 18, 2026Market cap $568.82MP/E –Yield 0.00%
Pacific Biosciences of California operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Pacific Biosciences of California's operating income for the twelve months ending Jun 30, 2026 was -$133.04M. For fiscal 2025 it was -$553.86M. The highest annual figure on record is -$29.13M in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$553.86M | – |
| FY2024 | Dec 31, 2024 | -$474.31M | – |
| FY2023 | Dec 31, 2023 | -$334.47M | – |
| FY2022 | Dec 31, 2022 | -$307.20M | – |
| FY2021 | Dec 31, 2021 | -$210.44M | – |
| FY2020 | Dec 31, 2020 | -$104.39M | – |
| FY2019 | Dec 31, 2019 | -$100.55M | – |
| FY2018 | Dec 31, 2018 | -$100.99M | – |
| FY2017 | Dec 31, 2017 | -$89.78M | – |
| FY2016 | Dec 31, 2016 | -$71.24M | – |
| FY2015 | Dec 31, 2015 | -$29.13M | – |
| FY2014 | Dec 31, 2014 | -$62.85M | – |
| FY2013 | Dec 31, 2013 | -$77.54M | – |
| FY2012 | Dec 31, 2012 | -$94.34M | – |
| FY2011 | Dec 31, 2011 | -$109.76M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$44.61M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.36M | – |
| Q4 FY2025 | Dec 31, 2025 | -$41.20M | – |
| Q3 FY2025 | Sep 30, 2025 | -$38.88M | – |
| Q2 FY2025 | Jun 30, 2025 | -$44.85M | – |
| Q1 FY2025 | Mar 31, 2025 | -$428.93M | – |
| Q4 FY2024 | Dec 31, 2024 | -$153.03M | – |
| Q3 FY2024 | Sep 30, 2024 | -$64.08M | – |
| Q2 FY2024 | Jun 30, 2024 | -$175.85M | – |
| Q1 FY2024 | Mar 31, 2024 | -$81.36M | – |
| Q4 FY2023 | Dec 31, 2023 | -$87.55M | – |
| Q3 FY2023 | Sep 30, 2023 | -$82.49M | – |
| Q2 FY2023 | Jun 30, 2023 | -$73.18M | – |
| Q1 FY2023 | Mar 31, 2023 | -$91.25M | – |
| Q4 FY2022 | Dec 31, 2022 | -$87.08M | – |
| Q3 FY2022 | Sep 30, 2022 | -$74.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$67.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$77.52M | – |
| Q4 FY2021 | Dec 31, 2021 | -$64.68M | – |
| Q3 FY2021 | Sep 30, 2021 | -$74.48M | – |
| Q2 FY2021 | Jun 30, 2021 | -$37.57M | – |
| Q1 FY2021 | Mar 31, 2021 | -$33.71M | – |
| Q4 FY2020 | Dec 31, 2020 | -$23.98M | – |
| Q3 FY2020 | Sep 30, 2020 | -$24.18M | – |
| Q2 FY2020 | Jun 30, 2020 | -$23.52M | – |
| Q1 FY2020 | Mar 31, 2020 | -$32.71M | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.92M | – |
| Q3 FY2019 | Sep 30, 2019 | -$28.11M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.38M | – |
| Q1 FY2019 | Mar 31, 2019 | -$30.13M | – |
| Q4 FY2018 | Dec 31, 2018 | -$30.62M | – |
| Q3 FY2018 | Sep 30, 2018 | -$24.67M | – |
| Q2 FY2018 | Jun 30, 2018 | -$21.75M | – |
| Q1 FY2018 | Mar 31, 2018 | -$23.95M | – |
| Q4 FY2017 | Dec 31, 2017 | -$20.53M | – |
| Q3 FY2017 | Sep 30, 2017 | -$21.57M | – |
| Q2 FY2017 | Jun 30, 2017 | -$24.39M | – |
| Q1 FY2017 | Mar 31, 2017 | -$23.30M | – |
| Q4 FY2016 | Dec 31, 2016 | -$17.87M | – |
| Q3 FY2016 | Sep 30, 2016 | -$16.74M | – |
See a number that looks wrong?